Cargando…

Immunohistochemical Expression of Platelet-Derived Growth Factor Receptor β (PDGFR-β) in Canine Cutaneous Peripheral Nerve Sheath Tumors: A Preliminary Study

SIMPLE SUMMARY: The peripheral nerve sheath tumors are relatively common neoplasms, belong to the soft tissue sarcomas group, and are poorly investigated in veterinary medicine; the diagnosis is complex, and therapeutic options are limited. The platelet-derived growth factor receptors, namely the β...

Descripción completa

Detalles Bibliográficos
Autores principales: Aluai-Cunha, Catarina, Matos, Augusto, Amorim, Irina, Carvalho, Fátima, Rêma, Alexandra, Santos, Andreia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319676/
https://www.ncbi.nlm.nih.gov/pubmed/35878362
http://dx.doi.org/10.3390/vetsci9070345
_version_ 1784755607919656960
author Aluai-Cunha, Catarina
Matos, Augusto
Amorim, Irina
Carvalho, Fátima
Rêma, Alexandra
Santos, Andreia
author_facet Aluai-Cunha, Catarina
Matos, Augusto
Amorim, Irina
Carvalho, Fátima
Rêma, Alexandra
Santos, Andreia
author_sort Aluai-Cunha, Catarina
collection PubMed
description SIMPLE SUMMARY: The peripheral nerve sheath tumors are relatively common neoplasms, belong to the soft tissue sarcomas group, and are poorly investigated in veterinary medicine; the diagnosis is complex, and therapeutic options are limited. The platelet-derived growth factor receptors, namely the β subunit, are an important class of tyrosine kinase receptors that can be activated by genetic alterations and contribute to the process of carcinogenesis, so the inhibition of this receptor is an important therapeutic target. Using the immunohistochemical technique, this study aims to evaluate the expression of this receptor in 19 samples, 10 malignant and 9 benign tumors. The results showed that the majority of benign tumors, about 67% of cases, expressed the receptor in less than 25% of neoplastic cells and, in 80% cases of malignant tumors, the receptor was expressed in more than 25% of neoplastic cells. It was also found that, in the larger tumors, the expression of this receptor was significantly higher. With these findings it seems reasonable to speculate that the drugs able to inhibit this receptor, such as toceranib, may be considered in the therapeutic approach of these tumors. ABSTRACT: As in humans, the prevalence of tumors in companion animals is increasing dramatically and there is a strong need for research on new pharmacological agents particularly for the treatment of those tumors that are resistant to conventional chemotherapy agents such as soft tissue sarcomas (STS). Because malignant (MPNST) and benign peripheral nerve sheath tumors (BPNST) are relatively common STS in dogs, the aim of this retrospective study was to evaluate the immunohistochemical (IHC) expression of PDGFR-β, contributing to its characterization as a potential target for their treatment. A total of 19 samples were included, 9 histologically classified as benign and the other 10 as malignant. The results showed diffuse immunoexpression in the cytoplasm of neoplastic cells. Six (66.7%) BPNST expressed the receptor in less than 25% of neoplastic cells and only three (33.3%) exhibited labelling in more than 25% of neoplastic cells. In contrast, all MPNST expressed PDGFR-β, and in 8 (80%) of these samples, the receptor was expressed in more than 25% of neoplastic cells, and only 2 (20%) cases expressed the receptor in less than 25% of neoplastic cells. PDGFR-β expression was significantly higher in MPNST and larger tumors, suggesting that drugs able to inhibit the activity of this tyrosine kinase receptor, such as toceranib, may be considered in the approach of unresectable tumors and/or in the context of adjuvant or neoadjuvant therapies.
format Online
Article
Text
id pubmed-9319676
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93196762022-07-27 Immunohistochemical Expression of Platelet-Derived Growth Factor Receptor β (PDGFR-β) in Canine Cutaneous Peripheral Nerve Sheath Tumors: A Preliminary Study Aluai-Cunha, Catarina Matos, Augusto Amorim, Irina Carvalho, Fátima Rêma, Alexandra Santos, Andreia Vet Sci Communication SIMPLE SUMMARY: The peripheral nerve sheath tumors are relatively common neoplasms, belong to the soft tissue sarcomas group, and are poorly investigated in veterinary medicine; the diagnosis is complex, and therapeutic options are limited. The platelet-derived growth factor receptors, namely the β subunit, are an important class of tyrosine kinase receptors that can be activated by genetic alterations and contribute to the process of carcinogenesis, so the inhibition of this receptor is an important therapeutic target. Using the immunohistochemical technique, this study aims to evaluate the expression of this receptor in 19 samples, 10 malignant and 9 benign tumors. The results showed that the majority of benign tumors, about 67% of cases, expressed the receptor in less than 25% of neoplastic cells and, in 80% cases of malignant tumors, the receptor was expressed in more than 25% of neoplastic cells. It was also found that, in the larger tumors, the expression of this receptor was significantly higher. With these findings it seems reasonable to speculate that the drugs able to inhibit this receptor, such as toceranib, may be considered in the therapeutic approach of these tumors. ABSTRACT: As in humans, the prevalence of tumors in companion animals is increasing dramatically and there is a strong need for research on new pharmacological agents particularly for the treatment of those tumors that are resistant to conventional chemotherapy agents such as soft tissue sarcomas (STS). Because malignant (MPNST) and benign peripheral nerve sheath tumors (BPNST) are relatively common STS in dogs, the aim of this retrospective study was to evaluate the immunohistochemical (IHC) expression of PDGFR-β, contributing to its characterization as a potential target for their treatment. A total of 19 samples were included, 9 histologically classified as benign and the other 10 as malignant. The results showed diffuse immunoexpression in the cytoplasm of neoplastic cells. Six (66.7%) BPNST expressed the receptor in less than 25% of neoplastic cells and only three (33.3%) exhibited labelling in more than 25% of neoplastic cells. In contrast, all MPNST expressed PDGFR-β, and in 8 (80%) of these samples, the receptor was expressed in more than 25% of neoplastic cells, and only 2 (20%) cases expressed the receptor in less than 25% of neoplastic cells. PDGFR-β expression was significantly higher in MPNST and larger tumors, suggesting that drugs able to inhibit the activity of this tyrosine kinase receptor, such as toceranib, may be considered in the approach of unresectable tumors and/or in the context of adjuvant or neoadjuvant therapies. MDPI 2022-07-09 /pmc/articles/PMC9319676/ /pubmed/35878362 http://dx.doi.org/10.3390/vetsci9070345 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Aluai-Cunha, Catarina
Matos, Augusto
Amorim, Irina
Carvalho, Fátima
Rêma, Alexandra
Santos, Andreia
Immunohistochemical Expression of Platelet-Derived Growth Factor Receptor β (PDGFR-β) in Canine Cutaneous Peripheral Nerve Sheath Tumors: A Preliminary Study
title Immunohistochemical Expression of Platelet-Derived Growth Factor Receptor β (PDGFR-β) in Canine Cutaneous Peripheral Nerve Sheath Tumors: A Preliminary Study
title_full Immunohistochemical Expression of Platelet-Derived Growth Factor Receptor β (PDGFR-β) in Canine Cutaneous Peripheral Nerve Sheath Tumors: A Preliminary Study
title_fullStr Immunohistochemical Expression of Platelet-Derived Growth Factor Receptor β (PDGFR-β) in Canine Cutaneous Peripheral Nerve Sheath Tumors: A Preliminary Study
title_full_unstemmed Immunohistochemical Expression of Platelet-Derived Growth Factor Receptor β (PDGFR-β) in Canine Cutaneous Peripheral Nerve Sheath Tumors: A Preliminary Study
title_short Immunohistochemical Expression of Platelet-Derived Growth Factor Receptor β (PDGFR-β) in Canine Cutaneous Peripheral Nerve Sheath Tumors: A Preliminary Study
title_sort immunohistochemical expression of platelet-derived growth factor receptor β (pdgfr-β) in canine cutaneous peripheral nerve sheath tumors: a preliminary study
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319676/
https://www.ncbi.nlm.nih.gov/pubmed/35878362
http://dx.doi.org/10.3390/vetsci9070345
work_keys_str_mv AT aluaicunhacatarina immunohistochemicalexpressionofplateletderivedgrowthfactorreceptorbpdgfrbincaninecutaneousperipheralnervesheathtumorsapreliminarystudy
AT matosaugusto immunohistochemicalexpressionofplateletderivedgrowthfactorreceptorbpdgfrbincaninecutaneousperipheralnervesheathtumorsapreliminarystudy
AT amorimirina immunohistochemicalexpressionofplateletderivedgrowthfactorreceptorbpdgfrbincaninecutaneousperipheralnervesheathtumorsapreliminarystudy
AT carvalhofatima immunohistochemicalexpressionofplateletderivedgrowthfactorreceptorbpdgfrbincaninecutaneousperipheralnervesheathtumorsapreliminarystudy
AT remaalexandra immunohistochemicalexpressionofplateletderivedgrowthfactorreceptorbpdgfrbincaninecutaneousperipheralnervesheathtumorsapreliminarystudy
AT santosandreia immunohistochemicalexpressionofplateletderivedgrowthfactorreceptorbpdgfrbincaninecutaneousperipheralnervesheathtumorsapreliminarystudy